As a nontraditional T-cell subgroup, γδT cells have gained popularity in the field of
immunotherapy in recent years. They have extraordinary antitumor potential and prospects …

Simple Summary The relationship between the immune system and tumours is currently one
of the most studied topics in the field of cancer. Previously, it was thought that a tumour could …

Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients
with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were …

The historical lack of preclinical models reflecting the genetic heterogeneity of multiple
myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this …

Simple Summary Multiple Myeloma (MM) is a hematologic malignancy caused by aberrant
plasma cell proliferation in the bone marrow (BM) and constitutes the second most common …

Multiple myeloma is an incurable cancer characterized by the uncontrolled growth of
malignant plasma cells nurtured within a permissive bone marrow microenvironment. While …

The proteasome inhibitor bortezomib induces apoptosis in multiple myeloma cells and has
transformed patient outcome. Using in vitro as well as in vivo immunodeficient and …

According to numerous animal studies, adverse environmental stimuli, including physical,
chemical, and biological factors, can cause low‐grade chronic inflammation and subsequent …

Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …

The cascade of metastasis in tumor cells, exhibiting organ-specific tendencies, may occur at
numerous phases of the disease and progress under intense evolutionary pressures. Organ …